G

Geron Corporation Tech Stack

FDA-approved telomerase inhibitor for blood cancers, scaling commercial execution

Biotechnology Research Foster City, California 201–500 employees Founded 1992 Public Company

Geron is a public biopharmaceutical company with an FDA-approved telomerase inhibitor (imetelstat) for lower-risk myelodysplastic syndromes, now expanding into other hematologic malignancies via Phase 3 trials. The hiring and project mix—heavy on sales directors, account planning, speaker programs, and HCP engagement—reveals a company transitioning from clinical validation to commercial scale. Pain-point data shows internal friction around territory alignment, budget governance, and speed-to-market, typical of a newly approved drug moving from launch into territory build-out.

Tech Stack 13 technologies

Core StackPower BI Intune Microsoft Office Excel Microsoft 365 Azure OneDrive SharePoint Teams Exchange Online Box Cisco Meraki Mimecast

What Geron Corporation Is Building

◆Challenges

Clinical or operational barriers
Improving finance organization efficiency
Incentive compensation design
Ic calculation accuracy
Territory alignment
Budget governance
Compliant spend processing
Speed-to-market
Innovating hcp engagement
Identifying data gaps and medical insights

▲Active Projects

Education on imetelstat
Account plan development
Congress presence
Speaker programs
Annual long-range planning process
Clinical presentations
Yearly budget
Rytelo advisory board
Rytelo speaker bureau
P2p programming

Hiring Activity

Steady25 roles · 10 in 30d

Department

Sales

11

Marketing

6

Finance

2

Healthcare

2

Research

2

Legal

1

Security

1

Seniority

Director

11

Senior

6

Mid

4

VP

4

Notable leadership hires: Business Director

Company intelligence

Find more companies like Geron Corporation by tech stack, pain points and active projects

Get started free

About Geron Corporation

Geron develops treatments targeting blood cancers through telomerase inhibition. The company holds the only FDA-approved oligonucleotide telomerase inhibitor and is conducting ongoing clinical trials in myelofibrosis and other hematologic malignancies. Based in Foster City, California, with 201–500 employees, Geron operates as a public company founded in 1992. The organization is structured around clinical development, regulatory affairs, and commercial operations—selling to hematologists and oncologists managing patients with transfusion-dependent anemia and other blood disorders. Current operational focus spans clinical presentations, advisory boards, speaker programs, and field organization build-out.

HeadquartersFoster City, California

Company Size201–500 employees

Founded1992

Hiring MarketsUnited States

Frequently Asked Questions

What is imetelstat and what is it approved for?

Imetelstat is the first FDA-approved telomerase inhibitor, indicated for treatment of certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. Geron is the sole company with an approved oligonucleotide telomerase inhibitor.

What other blood cancers is Geron studying?

Beyond LR-MDS, Geron is conducting clinical trials across other hematologic malignancies, including a pivotal Phase 3 trial in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF).